GEMoaB Monoclonals

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2020)

|

GEMoaB MonoclonalsCompany type| GmbH

|

Industry| Biotechnology
Pharmaceutical
Founded| 2011
Founder| Gerhard Ehninger, Michael Bachmann
Headquarters| Dresden, Germany

Key people

| Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger (CMO)[1]
Products| GEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA
Revenue| n.a.
Website| www.gemoab.com

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[2] [3] It was acquired by the new company AvenCell Therapeutics in 2021.[4][5]

## Company background

[edit]

See also: Chimeric antigen receptor T cell

To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[6]

## Scientific and strategic board

[edit]

The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).[7]

## Co-operations

[edit]

Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[8]

## Drugs currently under development

[edit]

* GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[9][10]
* GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[11]
* UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
* UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours

## Literatur

[edit]

* Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141\. doi:10.1038/s41598-020-59082-4, PMID 32034289.
* Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. doi:10.1182/blood-2018-99-113288.
* Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. doi:10.1080/2162402X.2019.1659095, PMID 31646084.
* C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967, doi:10.1038/leu.2013.18, PMID 23325142.

## See also

[edit]

* Gene therapy
* DKMS

## References

[edit]

1. ^ Leadership Team Leadership Team Archived 14 July 2021 at the Wayback Machine, Company Website, Retrieved: July 15, 2021
2. ^ Get to know GEMoaB[permanent dead link], Company Website, Retrieved: May 11, 2020
3. ^ "GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias". chemie-link.de. 9 March 2020. Retrieved 11 May 2020.
4. ^ "Clinical-stage biopharma company targets hard-to-treat cancers". AvenCell. Retrieved 12 February 2024.
5. ^ "Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company". Blackstone. 22 June 2021. Retrieved 12 February 2024.
6. ^ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S. e458, doi:10.1038/bcj.2016.61, PMID 27518241, PMC 5022178.
7. ^ Scientific and Strategic Advisory Board[permanent dead link], Company Website, Retrieved: May 11, 2020
8. ^ Our Partners[permanent dead link], Company Website, Retrieved: May 11, 2020
9. ^ AML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020
10. ^ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020
11. ^ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020

## External links

[edit]

* Official website